Pioneering the treatment of
fluid overload and oedema

Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.

We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.

This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.

Having substantially de-risked the technology, Renephra is raising £1.2million to design the TFR device, and to obtain the required regulatory approvals in Europe.

Recent News

Deepbridge Capital | April 2016
Renephra has received investment from DeepBridge Capital.

Deepbridge Capital

SBRI Healthcare | March 2016
Renephra has been awarded £100k SBRI Healthcare development contract for Urgent and Emergency Care Services.

“This work was commissioned and funded by the SBRI Healthcare programme. SBRI Healthcare is an NHS England initiative, championed by the Academic Health Science Networks (AHSNs). The views expressed in the publication are those of the author(s) and not necessarily those of the SBRI Healthcare programme or its stakeholders.”

SBRI Healthcare HCC
AHSN Network

MedTech Strategist | June 2015
Start-Ups to Watch: “Renephra. Home-Based Fluid Removal for Fluid Overload and Chronic Edema.” by Mary Stuart.


T:  +44 161 667 1089


Renephra Limited
MedTech Centre
Manchester Science Partnerships
Pencroft Way
M15 6JJ
Google Maps


© 2017  Renephra Ltd.  All rights reserved.